Trial
NCT04612790
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
AstraZeneca
Collaborators
—
Condition
Bullous Pemphigoid
Intervention
Benralizumab
Why stopped
Independent Data Monitoring Committee recommended terminating the study following a pre-planned analysis as the efficacy results did not meet the pre-defined futility guidelines. There were no new safety concerns identified from this analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-29